Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth Capital

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report)'s stock had its "buy" rating reiterated by Roth Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $116.00 price target on the stock, up from their prior price target of $92.00. Roth Capital's price target points to a potential upside of 26.53% from the company's current price.

A number of other research analysts also recently commented on the company. Jefferies Financial Group increased their target price on Verona Pharma PLC American Depositary Share from $95.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Cantor Fitzgerald lifted their target price on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. HC Wainwright boosted their price objective on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a "buy" rating in a research note on Monday, June 2nd. TD Cowen started coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, April 28th. They issued a "buy" rating and a $100.00 price target on the stock. Finally, Wells Fargo & Company boosted their price objective on shares of Verona Pharma PLC American Depositary Share from $93.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, April 30th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $91.11.

Verona Pharma PLC American Depositary Share Stock Performance

VRNA stock traded down $1.25 on Wednesday, hitting $91.68. The company had a trading volume of 444,640 shares, compared to its average volume of 1,317,452. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07. Verona Pharma PLC American Depositary Share has a 12-month low of $14.14 and a 12-month high of $94.45. The stock has a market cap of $7.43 billion, a price-to-earnings ratio of -45.78 and a beta of 0.21. The stock's 50-day simple moving average is $72.55 and its 200 day simple moving average is $61.14.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to analysts' expectations of $41.47 million. As a group, equities research analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In related news, Director Vikas Sinha sold 20,000 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $8.92, for a total value of $178,400.00. Following the completion of the sale, the director now directly owns 74,440 shares of the company's stock, valued at $664,004.80. This represents a 21.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark W. Hahn sold 400,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the transaction, the chief financial officer now owns 12,278,992 shares in the company, valued at approximately $139,980,508.80. This trade represents a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,885,800 shares of company stock valued at $19,134,481 in the last quarter. Corporate insiders own 4.80% of the company's stock.

Institutional Trading of Verona Pharma PLC American Depositary Share

Several hedge funds have recently made changes to their positions in the company. NBC Securities Inc. acquired a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter worth $34,000. Geneos Wealth Management Inc. lifted its position in shares of Verona Pharma PLC American Depositary Share by 44.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after acquiring an additional 193 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the 1st quarter worth approximately $48,000. NewEdge Advisors LLC purchased a new position in Verona Pharma PLC American Depositary Share in the 1st quarter valued at approximately $58,000. Finally, Vermillion Wealth Management Inc. acquired a new position in Verona Pharma PLC American Depositary Share during the fourth quarter worth $46,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.